financetom
NOV
financetom
/
Energy
/
NOV
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
NOV Inc.NOV
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

NOV Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production, and industrial and renewable energy sectors worldwide.

The company operates through three segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies.

It provides solids control and waste management equipment and services; portable power generation products; drill and wired pipes; drilling optimization and automation services; tubular inspection, repair, and coating services; instrumentation; measuring and monitoring services; downhole and fishing tools; steerable technologies; and drill bits.

The company also offers equipment and technologies for hydraulic fracture stimulation, including downhole multistage fracturing tools, pressure pumping trucks, blenders, sanders, hydration and injection units, flowline, and manifolds; coiled tubing units, and wireline units and tools; connections and liner hangers; onshore production consists of composite pipe, surface transfer and progressive cavity pumps, and artificial lift systems; and offshore production, such as floating production systems and subsea production technologies, as well as manufactures industrial pumps and mixers.

In addition, it provides substructures, derricks, and masts; cranes; jacking systems; pipe lifting, racking, rotating, and assembly systems; mud pumps; pressure control equipment; drives and generators; rig instrumentation and control systems; mooring, anchor, and deck handling machinery; equipment components for offshore wind construction vessels; and pipelay and construction systems.

Further, the company offers spare parts, repair, and rentals as well as comprehensive remote equipment monitoring, technical support, field service, and customer training.

The company was formerly known as National Oilwell Varco, Inc. and changed its name to NOV Inc. in January 2021.

NOV Inc. was founded in 1862 and is based in Houston, Texas.

Latest News >
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Aug 2, 2024
08:51 AM EDT, 08/02/2024 (MT Newswires) -- Atmus Filtration Technologies ( ATMU ) reported Q2 adjusted earnings Friday of $0.71 per diluted share, up from $0.63 a year earlier. Analysts polled by Capital IQ expected $0.58. Net sales for the quarter ended June 30 were $432.6 million, up from $413.6 million a year earlier. Analysts surveyed by Capital IQ expected...
Sector Update: Consumer
Sector Update: Consumer
Aug 2, 2024
08:48 AM EDT, 08/02/2024 (MT Newswires) -- Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) fell by 3.6% recently. Church & Dwight ( CHD ) shares fell by more than 4% after the consumer goods company said it expects Q3 adjusted...
Wayfair Analyst Urges Investors To 'Buy The Dip' As Macroeconomic Factors Affect Stock Performance
Wayfair Analyst Urges Investors To 'Buy The Dip' As Macroeconomic Factors Affect Stock Performance
Aug 2, 2024
Amid the turbulence in the consumer and retail sector, Wayfair Inc. ( W ) has been making headlines for its recent dip in stock performance. However, JPMorgan analyst Christopher Horvers is urging investors not to panic but instead “Buy the Dip,” as he emphasizes that the issues facing Wayfair ( W ) are macroeconomic rather than company-specific. Horvers maintains an...
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Aug 2, 2024
Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...
Copyright 2023-2026 - www.financetom.com All Rights Reserved